YCMi001-B-1

iPSC Line

Provider

External iPSC Databases

General iPSC Information

• Sung JJ et al. Generation of a gene edited hemophilia A patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR/Cas9. Stem cell research. 2020 Oct;48:101948.
• Ramamurthy RM et al. Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII. Frontiers in immunology. 2022;13:954984.
• Bhattacharjee G et al. Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications. Journal of controlled release : official journal of the Controlled Release Society. 2022 Mar;343:703-723.
• Jair Lara-Navarro I et al. Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives. The Tohoku journal of experimental medicine. 2022 Mar;256(3):197-207.
• De Pablo-Moreno Juan A. et al. Treatment of congenital coagulopathies, from biologic to biotechnological drugs: The relevance of gene editing (CRISPR/Cas). Thrombosis Research. 2023-11-00.
• Alayoubi Abdulfatah M. et al. CRISPR-Cas9 system: a novel and promising era of genotherapy for beta-hemoglobinopathies, hematological malignancy, and hemophilia. Annals of Hematology. 2024-06-00.
• Andriianov Vladimir et al. Application of Induced Pluripotent Stem Cells (iPSCs) in Hereditary and Viral Diseases of the Liver: Modeling and Treatment. International Journal of Molecular Sciences. 2025-09-26.
• Rajabi Zangi Ali et al. RNA therapeutics and their delivery methods: a paradigm for haemophilia management. Journal of Drug Targeting. 2026-05-13.

• YCMi001-B

General